Logo image
Price and Adoption of Exhalation Delivery System With Fluticasone, 2018-2023
Journal article   Peer reviewed

Price and Adoption of Exhalation Delivery System With Fluticasone, 2018-2023

Taylor S. Erickson, Katie M. Phillips, Akash M. Bhat, George A. Scangas, Alan D. Workman and Vinay K. Rathi
Otolaryngology-head and neck surgery, v 174(1), pp 280-284
Jan 2026
PMID: 41126661

Abstract

chronic rhinosinusitis exhalation delivery system intranasal corticosteroid markup nasal polyps price
FDA approved an exhalation delivery system with fluticasone (EDS-FLU) for treatment of chronic rhinosinusitis with (2017) and without (2024) nasal polyposis. Concerns have emerged that high prices may limit access, but little is known about the extent of adoption. We analyzed publicly available Securities and Exchange Commission filings and Medicare Part D spending data to characterize EDS-FLU utilization, spending, and prices between 2018 and 2023. During this period, annual EDS-FLU utilization and spending increased 10.3-fold (32,869 to 339,400 prescriptions) and 12-fold ($21.1 million to $252.9 million), respectively. Despite reductions in the manufacturer net price ($272.98 to $228.34 per prescription after rebates/discounts; relative difference −16.4%), the Medicare Part D point-of-sale price increased ($642.72 to $745.11; relative difference 15.9%). In 2023, pharmacy markup ($516.77) over acquisition costs accounted for 69.4% of the point-of-sale net price. Policy reforms limiting price inflation by pharmaceutical supply chain intermediaries are necessary to promote access and lower drug spending.

Metrics

1 Record Views

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Otorhinolaryngology
Surgery
Logo image